Effects of long-term (up to 5 years) open-label treatment with aripiprazole

被引：0
|
作者：
Kungel, M
Ebrecht, M
Modell, S
Werner, C
Spevakné-Göröcs, T
机构：
[1] Bristol Myers Squibb Co, Munich, Germany
[2] Otsuka Pharma GmbH, Frankfurt, Germany
来源：
PHARMACOPSYCHIATRY | 2005年 / 38卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：257 / 257
页数：1
相关论文
共 50 条
  • [1] Efficacy and tolerability of long-term (up to 5 years) open-label treatment with aripiprazole in schizophrenia
    Carson, W
    Ali, M
    Saha, A
    McQuade, R
    Owen, R
    Stock, E
    Yamamoto, Y
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S510 - S510
  • [2] LONG-TERM EFFECTS (UP TO 4 YEARS) OF ARIPIPRAZOLE ON MAINTENANCE TREATMENT FOR SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER: A POOLED OPEN-LABEL EXTENSION OF TWO CLINICAL TRIALS
    Baker, Ross A.
    Jin, Na
    Ali, Mirza W.
    Forbes, Robert A.
    Offord, Steven J.
    Carson, William H.
    Sanchez, Raymond
    McQuade, Robert D.
    Rahman, Zia
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S154 - S154
  • [3] PERSISTENCE OF TOFACITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES UP TO 7 YEARS
    Pope, J.
    Keystone, E.
    Jamal, S.
    Wang, L.
    Fallon, L.
    Woolcott, J.
    Lazariciu, I.
    Haraoui, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 245 - 245
  • [4] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8 Years
    Pope, Janet
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Haraoui, Boulos
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [5] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
    Pope, Janet E.
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Chapman, Douglass
    Haraoui, Boulos
    ACR OPEN RHEUMATOLOGY, 2019, 1 (02) : 73 - 82
  • [6] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Wood, Susan P.
    Terry, Ketti K.
    Nakamura, Hiroyuki
    Ohno, Yukako
    Gruben, David
    Benda, Birgitta
    Wang, Lisy
    Riese, Richard
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993
  • [7] Aripiprazole once-monthly for long-term maintenance treatment of schizophrenia: A 52-week open-label study
    Baker, R.
    Peters-Strickland, T.
    McQuade, R. D.
    Jin, N.
    Eramo, A.
    Perry, P. P.
    Johnson, B. R.
    Duca, A. R.
    Sanchez, R.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 64 - 64
  • [8] Aripiprazole once-monthly for long-term maintenance treatment of schizophrenia: a 52-week open-label study
    Peters-Strickland, T.
    Baker, R. A.
    McQuade, R.
    Jin, N.
    Eramo, A.
    Perry, P.
    Johnson, B.
    Duca, A.
    Sanchez, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S542 - S542
  • [9] An Open-Label Assessment of Aripiprazole in the Treatment of PTSD
    Robert, Sophie
    Hamner, Mark B.
    Durkalski, Valerie L.
    Brown, Mary W.
    Ulmer, Helen G.
    PSYCHOPHARMACOLOGY BULLETIN, 2009, 42 (01) : 69 - 80
  • [10] Open-Label Trial of Aripiprazole in the Treatment of Trichotillomania
    White, Matthew P.
    Koran, Lorrin M.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (04) : 503 - 506
12345